Citable filing context
GEHC's research view summarizes recent SEC filing context, starting with management_change from Sep 22, 2026.
| Filed | Item | Context |
|---|---|---|
| Sep 22, 2026 | management_change | GE HealthCare appointed Pascal Desroches to its Board of Directors, effective January 4, 2027. |
| Aug 18, 2026 | management_change | GE HealthCare appointed William K. Grogan as Chief Financial Officer, effective September 14, 2026. |
| Jul 29, 2026 | other | GE HealthCare reorganized its reportable segments, combining Imaging and Advanced Visualization Solutions into a new Advanced Imaging Solutions segment. |
| Jul 29, 2026 | Guidance: adjusted_ebit_margin | 15.40 to 15.70 |
| Jul 29, 2026 | Guidance: adjusted_effective_tax_rate | 20.00 to 21.00 |
| Jul 29, 2026 | Guidance: adjusted_eps | 4.80 to 5.00 |
| Jul 29, 2026 | mda_quarterly | GE HealthCare reorganized its operations in the second quarter of 2026, consolidating its Imaging and Advanced Visualization Solutions businesses into a new reportable segment, Advanced Imaging Solutions (AIS). The company now operates through three segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS). Financial performance in the first half of 2026 was significantly influenced by global trade volatility. U.S. tariffs negatively impacted operating income by $156 million, though the company successfully secured $107 million in refunds during the second quarter. Despite these headwinds, total revenues grew 6.6% to $10.4 billion, driven by strong organic growth in PDx (12.3%) and AIS (4.5%). Conversely, the PCS segment faced a 10.9% organic revenue decline due to operational and fulfillment challenges. Geopolitical instability, particularly in the Middle East, and inflationary pressures on raw materials like memory chips and logistics costs continue to pose risks. In China, the company is navigating increased local competition and volume-based procurement policies. GE HealthCare maintains a solid liquidity position with $2.1 billion in cash and access to $3.5 billion in revolving credit facilities. Capital allocation remains focused on strategic growth, highlighted by the $2.3 billion acquisition of Intelerad during the period. |
| Apr 29, 2026 | mda_quarterly | GE HealthCare reported total revenues of $5.13 billion for the first quarter of 2026, representing 7.4% reported growth and 2.9% organic growth. Performance was driven by strength in the Pharmaceutical Diagnostics (PDx), Imaging, and Advanced Visualization Solutions (AVS) segments, though the Patient Care Solutions (PCS) segment declined 6.5% due to the timing of installations. Regionally, the company saw double-digit growth in EMEA and the Rest of World, while the China market faced a 4.4% revenue decline amid increased local competition and volume-based procurement policies. Profitability faced significant headwinds, with operating income falling 18.2% to $515 million. Margins were compressed by 310 basis points, primarily due to cost inflation and the impact of incremental global tariffs, which negatively affected operating income by approximately $90 million. Additionally, the company incurred higher engineering costs for new product design follow-through. Despite these pressures, GE HealthCare maintains a solid liquidity position with $2.29 billion in cash and access to $3.5 billion in revolving credit facilities. Capital allocation remains active, highlighted by the $2.3 billion acquisition of Intelerad and $100 million in share repurchases. Management continues to monitor geopolitical instability and trade frictions, which remain key risks to supply chain stability and future financial performance. |
Source: SEC EDGAR filing text and events; period Sep 22, 2026; filed Sep 22, 2026.
GEHC company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.